Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Transplantation. 2012 Sep 27;94(6):562-8. doi: 10.1097/TP.0b013e3182646bf1.
Allogeneic hematopoietic cell transplantation provides a reliable method for inducing tolerance toward solid organ grafts. However, this procedure can result in graft-versus-host disease, thereby limiting its application. Here, we test the hypothesis that mixed chimerism can be intentionally reverted to host hematopoiesis without rejection of a kidney graft.
Recipient dogs were given 2-Gy total-body irradiation (TBI) before and a short course of immunosuppression after marrow infusion from dog leukocyte antigen-identical littermates. All dogs achieved stable mixed chimerism. After a mean of 20 weeks, one cohort of dogs received kidney transplants from their respective marrow donors. Subsequently, recipients were reconditioned with 2-Gy TBI and given autologous granulocyte colony-stimulating factor-mobilized leukocytes (recipient leukocyte infusion [RLI]) that had been collected before marrow transplantation.
Dogs receiving a second TBI and RLI without a kidney transplant rejected their donor hematopoietic graft within 3 weeks. Dogs that received kidney grafts, followed by a second TBI and RLI, rejected their marrow graft without rejecting their transplanted kidneys for periods greater than 1 year.
Mixed chimerism may be clinically reverted to 100% recipient without rejection of a kidney allograft. This finding may have application toward minimizing the risk of graft-versus-host disease in solid organ transplantation patients given hematopoietic cell transplantation from human leukocyte antigen-identical donors.
异基因造血细胞移植为诱导对实体器官移植物的耐受提供了一种可靠的方法。然而,该程序可能导致移植物抗宿主病,从而限制了其应用。在这里,我们测试了这样一种假设,即混合嵌合体可以在不排斥肾脏移植物的情况下被有意地逆转为主导的造血。
受体犬在骨髓输注前接受 2Gy 全身照射(TBI),并在骨髓输注后接受短期免疫抑制治疗。所有犬均实现了稳定的混合嵌合体。平均 20 周后,一组犬接受了来自各自骨髓供体的肾脏移植。随后,受者接受 2GyTBI 预处理,并接受在骨髓移植前采集的自体粒细胞集落刺激因子动员的白细胞(受者白细胞输注[RLI])。
未接受肾脏移植而接受第二次 TBI 和 RLI 的犬在 3 周内排斥了供体造血移植物。接受肾脏移植,随后接受第二次 TBI 和 RLI 的犬在 1 年以上的时间内排斥骨髓移植物而不排斥移植肾脏。
混合嵌合体可能在临床上被逆转至 100%受者,而不排斥肾脏同种异体移植物。这一发现可能有助于减少接受人类白细胞抗原相同供体造血细胞移植的实体器官移植患者发生移植物抗宿主病的风险。